Pluri Inc.

Pluri Inc. is a biotechnology company specializing in placenta-based cell therapy products for treating inflammatory, muscle injuries, and hematologic conditions. Their flagship product, PLX-PAD, is undergoing Phase III clinical trials for muscle recovery post-hip fracture surgery, Phase II trials for COVID-19-associated acute respiratory distress syndrome, and Phase I/II trials for steroid-refractory graft versus host disease. Additionally, they are developing PLX-R18 for incomplete hematopoietic recovery post-hematopoietic cell transplantation and for acute radiation syndrome treatment. The company generates revenue through the development and commercialization of these cell therapy products for various medical conditions.

Products

• PLX-PAD for muscle recovery and acute respiratory distress syndrome

• PLX-R18 for hematopoietic recovery and acute radiation syndrome